{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T05:42:06Z","timestamp":1775540526295,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T00:00:00Z","timestamp":1710979200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.neurol.2024.03.003","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T20:35:02Z","timestamp":1712262902000},"page":"378-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3"],"prefix":"10.1016","volume":"180","author":[{"given":"N.","family":"D\u00e9glon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neurol.2024.03.003_bib0115","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1474-4422(23)00068-6","article-title":"Autosomal dominant cerebellar ataxias: new genes and progress towards treatments","volume":"22","author":"Coarelli","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2024.03.003_bib0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ng1194-221","article-title":"CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1","volume":"8","author":"Kawaguchi","year":"1994","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.neurol.2024.03.003_bib0125","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41588-024-01653-6","article-title":"Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum","volume":"56","author":"Matlik","year":"2024","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.neurol.2024.03.003_bib0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/hmg\/ddi472","article-title":"Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and sequestration of non-expanded ataxin-3","volume":"15","author":"Haacke","year":"2006","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.neurol.2024.03.003_bib0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cell.2009.04.042","article-title":"Defining the human deubiquitinating enzyme interaction landscape","volume":"138","author":"Sowa","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.neurol.2024.03.003_bib0140","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.cell.2005.11.007","article-title":"A genomic and functional inventory of deubiquitinating enzymes","volume":"123","author":"Nijman","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.neurol.2024.03.003_bib0145","doi-asserted-by":"crossref","first-page":"e1004937","DOI":"10.1371\/journal.pgen.1004937","article-title":"Ataxin-3, DNA damage repair, and SCA3 cerebellar degeneration: on the path to parsimony?","volume":"11","author":"Ward","year":"2015","journal-title":"PLoS Genet"},{"issue":"1","key":"10.1016\/j.neurol.2024.03.003_bib0150","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s12017-010-8137-3","article-title":"Mouse ataxin-3 functional knock-out model","volume":"13","author":"Switonski","year":"2011","journal-title":"Neuromolecular Med"},{"key":"10.1016\/j.neurol.2024.03.003_bib0155","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3389\/fnins.2020.00571","article-title":"Gene deregulation and underlying mechanisms in spinocerebellar ataxias with polyglutamine expansion","volume":"14","author":"Niewiadomska-Cimicka","year":"2020","journal-title":"Front Neurosci"},{"issue":"3","key":"10.1016\/j.neurol.2024.03.003_bib0160","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/mt.2013.279","article-title":"Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy","volume":"22","author":"Keiser","year":"2014","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.neurol.2024.03.003_bib0165","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nsmb1215","article-title":"A toxic monomeric conformer of the polyglutamine protein","volume":"14","author":"Nagai","year":"2007","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"10.1016\/j.neurol.2024.03.003_bib0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/jnc.14541","article-title":"Machado-Joseph disease\/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy","volume":"148","author":"Matos","year":"2019","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.neurol.2024.03.003_bib0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/WCO.0000000000000832","article-title":"Recent therapeutic prospects for Machado-Joseph disease","volume":"33","author":"Costa","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.neurol.2024.03.003_bib0180","doi-asserted-by":"crossref","DOI":"10.1002\/ana.26713","article-title":"Antisense oligonucleotide silencing reverses abnormal neurochemistry in spinocerebellar ataxia 3 mice","author":"McLoughlin","year":"2023","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2024.03.003_bib0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrneurol.2016.190","article-title":"Gene therapy: gene-editing therapy for neurological disease","volume":"13","author":"McMahon","year":"2017","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2024.03.003_bib0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-targeted deletion of polyglutamine in spinocerebellar ataxia type 3-derived induced pluripotent stem cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev"},{"issue":"17\u201318","key":"10.1016\/j.neurol.2024.03.003_bib0195","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1089\/hum.2023.109","article-title":"Limitations of dual-single guide RNA CRISPR strategies for the treatment of central nervous system genetic disorders","volume":"34","author":"Duarte","year":"2023","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.1016\/j.neurol.2024.03.003_bib0200","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41398-021-01605-2","article-title":"CRISPR\/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells","volume":"11","author":"He","year":"2021","journal-title":"Transl Psychiatry"},{"issue":"6","key":"10.1016\/j.neurol.2024.03.003_bib0205","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molmed.2021.03.010","article-title":"Adeno-associated virus vector for central nervous system gene therapy","volume":"27","author":"Zhu","year":"2021","journal-title":"Trends Mol Med"},{"issue":"7","key":"10.1016\/j.neurol.2024.03.003_bib0210","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-019-0478-3","article-title":"Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease","volume":"25","author":"Zeitler","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.neurol.2024.03.003_bib0215","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1038\/ncomms13272","article-title":"Contracting CAG\/CTG repeats using the CRISPR-Cas9 nickase","volume":"7","author":"Cinesi","year":"2016","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.neurol.2024.03.003_bib0220","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.neuron.2023.04.021","article-title":"CRISPR for neuroscientists","volume":"111","author":"Kalamakis","year":"2023","journal-title":"Neuron"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378724004788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T01:18:26Z","timestamp":1716599906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378724004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0035378724004788"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2024.03.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene editing as a therapeutic strategy for spinocerebellar ataxia type-3","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2024.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}